RGS6 Human shRNA Lentiviral Particle (Locus ID 9628)

CAT#: TL309831V

RGS6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Specifications

Product Data

• Locus ID: 9628
• Synonyms: GAP; HA117; S914
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001204416, NM_001204417, NM_001204418, NM_001204419, NM_001204420, NM_001204421, NM_001204422, NM_001204423, NM_001204424, NM_004296, NR_135235, BC104877, BC113572, BC143699, NM_001370270, NM_001370271, NM_001370272, NM_001370273, NM_001370274, NM_001370276, NM_001370278, NM_001370281, NM_001370284, NM_001370290, NM_001370275, NM_001370277, NM_001370279, NM_001370280, NM_001370282, NM_001370283, NM_001370286, NM_001370287, NM_001370288, NM_001370289, NM_001370291, NM_001370292, NM_001370293, NM_001370294
• Summary: This gene encodes a member of the RGS (regulator of G protein signaling) family of proteins, which are defined by the presence of a RGS domain that confers the GTPase-activating activity of these proteins toward certain G alpha subunits. This protein also belongs to a subfamily of RGS proteins characterized by the presence of DEP and GGL domains, the latter a G beta 5-interacting domain. The RGS proteins negatively regulate G protein signaling, and may modulate neuronal, cardiovascular, lymphocytic activities, and cancer risk. Many alternatively spliced transcript variants encoding different isoforms with long or short N-terminal domains, complete or incomplete GGL domains, and distinct C-terminal domains, have been described for this gene, however, the full-length nature of some of these variants is not known. [provided by RefSeq, Mar 2011]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).